Trial Profile
Doppler Quantitative Evaluation and Follow-up Over 12 Months in RA Patients With Moderate and High Disease Activity Who Are Candidates for Biologic add-on Therapy With Adalimumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Aug 2018
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms Muscara
- 24 Apr 2018 Status changed from recruiting to completed.
- 01 Dec 2016 Planned End Date changed from 1 Sep 2016 to 1 Sep 2017.
- 01 Dec 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2017.